Exhibit 99.1 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in AML IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) selective inhibitor; Phase 1 trial planned to begin in the second half of 2024 with primary target population in BRG1 mutated non-smal ...

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation therapeutic in AML IND filing submitted for FHD-909, a first-in-class oral BRM (SMARCA2) selective inhibitor; Phase 1 trial planned to begin in the second half of 2024 with primary target population in BRG1 mutated non-small cell lung cancer; first BRM selective inhibitor to enter the clinic IND-enabling studies fo ...

Foghorn Therapeutics Inc.新药FHD-909 - Foghorn Therapeutics Inc.在2024年美国癌症研究协会年会上宣布了潜在首创药物FHD-909的新的临床前数据[1] - FHD-909是一种BRM（SMARCA2）选择性抑制剂，对BRG1突变癌症在临床前表现出良好的耐受性和剂量依赖的单药活性[2] - FHD-909是一种高效、异位和口服可用的小分子，通过选择性抑制BRM的ATP酶活性，对BRG1突变的肿瘤显示出显著的抗肿瘤活性[8] Foghorn公司的新项目 - Foghorn公司的首席科学官Steve Bellon博士表示，他们的选择性CBP和选择性EP300降解剂项目在固体肿瘤中表现出显著的抑制肿瘤生长活性，且无血小板减少或贫血等副作用[3] Foghorn公司电话会议 - Foghorn公司将于当天下午5点举行电话会议和网络研讨会，以审查重要的管道更新[6]

CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 23rd Annual Needham Virtual Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a ...

Foghorn Therapeutics Inc. (FHTX)股票表现 - 上周收盘价为$7.13，较过去四周上涨5%[1] - 华尔街分析师的短期价格目标显示，FHTX股票仍有105.8%的上涨潜力，平均价格目标为$14.67[1] - FHTX目前具有Zacks Rank 2（买入），这意味着它在我们根据与盈利预期相关的四个因素对4000多只股票进行排名时处于前20%[10]

Investors might want to bet on Foghorn Therapeutics Inc. (FHTX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changin ...

Foghorn Therapeutics Inc. (FHTX) closed the last trading session at $6.54, gaining 5.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $14.67 indicates a 124.3% upside potential.The average comprises six short-term price targets ranging from a low of $6 to a high of $20, with a standard deviation of $5.61. While the lowest estimate indicates a decline of 8.3% from the current pric ...

财务表现 - Foghorn Therapeutics Inc. (FHTX)在上个季度每股亏损为0.57美元，超过了Zacks Consensus Estimate的0.79美元的亏损预期[1] - 公司在过去四个季度中，三次超过了市场预期的每股收益[2] - Foghorn Therapeutics Inc.在2023年12月份的季度实现了5.77百万美元的营收，超过了Zacks Consensus Estimate的17.59%[3] 股价表现 - 公司股价自年初以来上涨了约5.3%，略低于标普500指数的涨幅[5] 投资建议 - 公司的盈利前景将影响股价的短期走势，投资者可以关注管理层在财报电话会议中的表态[4] - Foghorn Therapeutics Inc.的盈利预期将影响股价走势，投资者可以关注盈利预期的变化[6] 行业排名 - 投资者应该留意行业前景对股票表现的影响，医药行业目前在Zacks行业排名中处于前36%[10]

Foghorn Therapeutics Inc.概况 - Foghorn Therapeutics Inc.是一家临床阶段的生物技术公司，专注于开发一类新型药物，通过纠正异常基因表达来治疗严重疾病[1] - Foghorn Therapeutics Inc.的Gene Traffic Control®平台和广泛的产品管道有潜力改变患有各种疾病的人们的生活[1] - Foghorn Therapeutics Inc.的现金、现金等价物和可市场化证券截至2023年12月31日为2.341亿美元，提供资金支持至2026年上半年[1]

现金及资金情况 - Foghorn Therapeutics Inc. 2023年12月31日的现金、现金等价物和可市场出售证券总额为234.1百万美元，提供现金运营至2026年上半年[1] 新药研发计划 - Foghorn预计在未来四年内至少推出六个新的面向重要肿瘤患者群体的IND，反映了其精准医学平台持续的生产力[1] - Foghorn与Lilly合作，Lilly计划在2024年第二季度为FHD-909提交IND，主要针对非小细胞肺癌患者群体[1] 药物研发进展 - Foghorn的CBP选择性降解剂在结直肠癌体内模型中显示出显著的肿瘤生长抑制作用[1] - Foghorn的EP300选择性降解剂在AR+ enzalutamide前列腺体内模型中显示出强效的细胞抗增殖和体内肿瘤生长抑制作用[1]